These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 7523734)

  • 21. Voluntary screening program for prostate cancer: detection rate and cost.
    Abramson N; Cotton S; Eckels R; Baldock J
    South Med J; 1994 Aug; 87(8):785-8. PubMed ID: 7519789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians.
    Coley CM; Barry MJ; Fleming C; Mulley AG
    Ann Intern Med; 1997 Mar; 126(5):394-406. PubMed ID: 9054286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer: who to screen, and what the results mean.
    Small EJ
    Geriatrics; 1993 Dec; 48(12):28-30, 35-8. PubMed ID: 7504646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
    Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
    Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The socioeconomic implications of prostate-specific antigen screening.
    Benoit RM; Naslund MJ
    Urol Clin North Am; 1997 May; 24(2):451-8. PubMed ID: 9126243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. American Cancer Society--National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen.
    Mettlin C; Murphy GP; Ray P; Shanberg A; Toi A; Chesley A; Babaian R; Badalament R; Kane RA; Lee F
    Cancer; 1993 Feb; 71(3 Suppl):891-8. PubMed ID: 7679042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early prostate cancer: diagnostic costs of screening transrectal US and digital rectal examination.
    Torp-Pedersen ST; Littrup PJ; Lee F; Mettlin C
    Radiology; 1988 Nov; 169(2):351-4. PubMed ID: 3140290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of a prostate cancer screening program in France: a decision model.
    Perez-Niddam K; Thoral F; Charvet-Protat S
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):167-73. PubMed ID: 10612016
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen].
    Ciatto S; Bonardi R; Mazzotta A; Lombardi C; Santoni R; Cardini S; Zappa M
    Radiol Med; 1994 Oct; 88(4):453-7. PubMed ID: 7527916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The status of prostate cancer early detection.
    Mettlin C
    Cancer; 1993 Aug; 72(3 Suppl):1050-5. PubMed ID: 7687518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project.
    Kane RA; Littrup PJ; Babaian R; Drago JR; Lee F; Chesley A; Murphy GP; Mettlin C
    Cancer; 1992 Mar; 69(5):1201-7. PubMed ID: 1371234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection.
    Nichol MB; Wu J; An JJ; Huang J; Denham D; Frencher S; Jacobsen SJ
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):253-61. PubMed ID: 21537346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Screening of prostate carcinoma].
    Trinkler FB
    Ther Umsch; 1995 Jun; 52(6):393-8. PubMed ID: 7541568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.